ZVSA (ZyVersa Therapeutics, Inc.) חוב לטווח קצר להון

The quotes provided below confirm the resilience of ZyVersa Therapeutics (ZVSA), which develops advanced treatments for renal pathologies and inflammation. Growth is driven by the study of IC 100 and VAR 200 drugs, as well as strategic partnerships. The company solidifies its status as a scientific leader through unique therapy methods, with the indicator standing at 0.00. Operations in the US provide full protection from geopolitical risks and trade restrictions.

ZyVersa Therapeutics' development of innovative drugs to combat nephrological pathologies requires significant liquid resources; therefore, this ratio of loans under one year to equity measures the company's dependence on short-term debt financing relative to its own funds. An increase in this coefficient signals elevated refinancing risks, whereas its decline confirms the business's financial stability during the clinical trial period.